The AACR Cancer Disparities Progress Report 2024 is available. The report provides a comprehensive overview of the latest research on cancer disparities and calls for policies to reduce disparities and achieve cancer health equity.
Read the ReportThanks to spectacular research-driven advances, more than 18 million people in the United States and millions more worldwide are cancer survivors living with, through, and beyond their disease.
Learn MoreRead the stories of cancer survivors and patients featured in the new AACR Cancer Disparities Progress Report 2024.
Read the ReportMore than 25,000 cases of brain and other nervous system cancers are expected to be diagnosed in the U.S. this year. May is Brain Cancer Awareness Month. Learn more about these cancers.
Learn MoreGet updates on research driven advances in cancer science and medicine including the recent AACR Annual Meeting 2024 in San Diego on the AACR Blog.
Read the AACR BlogThe Week in Cancer News: A roundup of significant cancer research news from the past week, selected by the staff of Cancer Today magazine.
Learn MoreWhether honoring a special person or a special day, a donation to the American Association for Cancer Research has a lasting impact.
Donate NowSession recordings are available for viewing to registered attendees through July 10. Registration remains open for the on-demand virtual meeting.
The AACR Cancer Disparities Progress Report 2024 outlines the complex interplay of factors that drive and perpetuate cancer health disparities and calls for a collaborative approach to achieve health equity.
Learn MoreThe AACR and its more than 58,000 members worldwide are advancing a scientifically bold agenda against the collection of diseases we call cancer.
Learn MoreDr. Winn, chair of the AACR Cancer Disparities Progress Report 2024 steering committee, discusses the many factors that drive and perpetuate cancer health disparities.
Learn Morepercent decrease of the overall age-adjusted cancer death rate in the U.S. from 1991 to 2020
Learn Moretherapeutics were approved for new or expanded uses by the FDA from Aug. 1, 2022, to July 31, 2023
Learn Moremillion cancer survivors in the U.S. are living with, through, and beyond their disease thanks to research
Learn More